APEXIAN PHARMACEUTICALS
Apex Therapeutics is an emerging clinical-stage biotechnology company founded on the scientific discoveries of Dr. Mark R. Kelley, whose groundbreaking work on APE1/Ref-1 redox protein signaling at the Indiana University School of Medicine has provided a unique insight into this novel biological target. It was founded in 2005 and headquartered in Indianapolis, Indiana.
APEXIAN PHARMACEUTICALS
Social Links:
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2005-01-01
Address:
Indianapolis, Indiana, United States
Country:
United States
Website Url:
http://www.apexianpharma.com
Total Employee:
1+
Status:
Active
Contact:
(317) 684-9106
Email Addresses:
[email protected]
Total Funding:
6.88 M USD
Technology used in webpage:
Euro U.S. Server Location CreativeWork Schema
Similar Organizations
Aeovian Pharmaceuticals
Aeovian Pharmaceuticals aims to discover, develop, and commercialize therapeutics for the treatment of rare and age-related diseases.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Pliant Therapeutics
Pliant Therapeutics focuses on discovering, developing, and commercializing breakthrough treatments for fibrotic diseases.
Recro Pharma
Recro Pharma is a pharmaceutical company developing non-opioid therapeutics for the treatment of pain.
Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical focuses on the development of various products for the treatment of rare and ultra-rare diseases.
Zogenix
Zogenix develops and commercializes products for the treatment of central nervous system disorders and pain.
Current Employees Featured
Founder
Investors List
IU Ventures
IU Ventures investment in Venture Round - Apexian Pharmaceuticals
Elevate Ventures
Elevate Ventures investment in Series A - Apexian Pharmaceuticals
BioCrossroads
BioCrossroads investment in Venture Round - Apexian Pharmaceuticals
IU Ventures
IU Ventures investment in Seed Round - Apexian Pharmaceuticals
Official Site Inspections
http://www.apexianpharma.com Semrush global rank: 9 M Semrush visits lastest month: 445
- Host name: cloudproxy10107.sucuri.net
- IP address: 192.124.249.107
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Apexian Pharmaceuticals"
Apexian Pharmaceuticals - Crunchbase Company Profile & Funding
Contact Email [email protected] Phone Number (317) 684-9106 Apex Therapeutics is an emerging clinical-stage biotechnology company founded on the scientific discoveries of Dr. …See details»
apexianpharma.com
We would like to show you a description here but the site won’t allow us.See details»
Overview, News & Similar companies - ZoomInfo.com
Oct 28, 2019 Apexian Pharmaceuticals contact info: Phone number: (317) 684-9196 Website: www.apexianpharma.com What does Apexian Pharmaceuticals do? Apexian Pharmaceuticals …See details»
Apexian Pharmaceuticals Company Profile | Management and
Www.apexianpharma.com Apexian Pharmaceuticals Profile and History Apexian Pharmaceuticals is a patient-centered biotechnology company dedicated to developing novel compounds that …See details»
APEXIAN PHARMACEUTICALS, INC. - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for APEXIAN PHARMACEUTICALS, INC. of Indianapolis, IN. Get the latest business insights from Dun & …See details»
Apexian Pharmaceuticals - PitchBook
Information on valuation, funding, cap tables, investors, and executives for Apexian Pharmaceuticals. Use the PitchBook Platform to explore the full profile.See details»
Apexian Pharmaceuticals - Products, Competitors, Financials, …
Headquarters Location. 20 N Meridian Street Suite 801. Indianapolis, Indiana, 46204, United States. 317-684-9196See details»
ApeX Therapeutics changes name to Apexian Pharmaceuticals to …
Oct 25, 2016 ApeX Therapeutics, a clinical stage biotechnology company focused on developing novel compounds to treat cancer, today announced that it has changed its corporate name to …See details»
Apexian Pharmaceuticals - Craft
Apexian Pharmaceuticals is a biotechnology company that provides medicines for cancer. It focuses on inflammatory disorders and tumorigenesis, including cancers of the colon, …See details»
Apexian Pharmaceuticals, Inc. | VentureRadar
Website: http://www.apexianpharma.com/ Develops innovative therapies targeting APE1/Ref-1 protein to treat various inflammatory disorders and cancers, including colon ...See details»
Apexian Pharmaceuticals | Elevate Ventures Job Board
Apexianpharma.com. Locations. Indianapolis, IN, USA. industry. Biotechnology · DeepTech · Health. Size. 1 - 10 employees. Stage. Other. founded in. 2005. Apex Therapeutics is an …See details»
Apexian Pharmaceuticals is Closing a Series A Round to Initiate …
Nov 29, 2017 To learn more about Apexian Pharmaceuticals, please visit the company's website at www.ApexianPharma.com Contacts Apexian Pharmaceuticals Roger Miller, 844-463-3330 …See details»
Apexian Pharmaceuticals is Closing a Series A Round to ... - BioSpace
Nov 29, 2017 INDIANAPOLIS--(BUSINESS WIRE)-- Apexian Pharmaceuticals, Inc., an Indiana-based clinical stage biotechnology company developing novel compounds to treat cancer, …See details»
Biotech, Pharmaceutical and Clinical Research Jobs | BioSpace
Biotech, Pharmaceutical and Clinical Research Jobs | BioSpaceSee details»
NIH Awards Grant for Research on Apexian's APX3330 as …
Oct 29, 2018 Please visit www.ApexianPharma.com for more information. Contacts. Apexian Pharmaceuticals Christy Denault, 317-417-6322 Release Summary.See details»
Apexian Pharmaceuticals Opens Phase 1 Clinical Study of APX3330 …
Jan 31, 2018 To learn more about Apexian Pharmaceuticals, please visit the company's website at www.ApexianPharma.com Contacts Apexian Pharmaceuticals Steve Carchedi, 844-463 …See details»
APX3330 Phase I Oncology Trial Presented at AACR-NCI-EORTC …
INDIANAPOLIS, October 28, 2019 (Newswire.com) - Apexian Pharmaceuticals, Inc., a clinical-stage drug development company focused on advancing APX3330 for the treatment of …See details»
Apexian Pharmaceuticals Preclinical Studies With APX3330 Shut …
Dec 19, 2018 Email: [email protected] Roger D. Miller, COO Telephone: 844-463-3330 x100 Contacts Email: [email protected] Roger D. Miller, COO Telephone: 844-463 …See details»
Apexian Pharmaceuticals' Clinical Candidate, APX3330, to Be …
INDIANAPOLIS, July 2, 2019 /PRNewswire/ -- Apexan Pharmaceuticals, Inc. is pleased to announce that The National Heart, Lung and Blood Institute (NHLBI) of the National Institutes …See details»